. 2023 Mar 14;23:245. doi: 10.1186/s12885-023-10703-x

Table 1.

Baseline data of BC patients receiving NAC

Factors		Non-pCR (N = 55)	pCR (N = 57)	Total	X²	P
Age (Years)	<44.5	9	16	25	2.212	0.137
Age (Years)	≥ 44.5	46	41	87	2.212	0.137
Menarche age (Years)	<13.5	27	35	62	1.717	0.190
Menarche age (Years)	≥ 13.5	28	22	50	1.717	0.190
Menstrual states	No	13	15	28	0.107	0.743
Menstrual states	Yes	42	42	84	0.107	0.743
Menopausal age (Years)	<51.5	37	30	67	3.614	0.057
Menopausal age (Years)	≥ 51.5	5	12	17	3.614	0.057
Primiparous age (Years)	<22.5	24	32	56	1.751	0.186
Primiparous age (Years)	≥ 22.5	31	25	56	1.751	0.186
Number of births	<3	43	50	93	1.808	0.179
Number of births	≥ 3	12	7	19	1.808	0.179
cT	1/2	45	47	92	0.008	0.930
cT	3/4	10	10	20	0.008	0.930
cN	0/1	37	35	72	0.517	0.472
cN	2/3	14	18	32	0.517	0.472
cM	0	50	52	102		1.000^a
cM	1	2	3	5		1.000^a
Axillary lymph nodes	Negative	11	6	17	1.951	0.162
Axillary lymph nodes	Posotive	14	51	65	1.951	0.162
Pathological type	IDC	55	53	108		0.119^a
Pathological type	Other	0	4	4		0.119^a
Grade	1/2	47	34	81	4.764	0.029
Grade	3	7	15	22	4.764	0.029
ER	Negative	16	28	44	4.404	0.036
ER	Positive	30	29	59	4.404	0.036
PR	Negative	19	27	46	1.696	0.193
PR	Positive	35	30	65	1.696	0.193
HER-2	Negative	13	8	21	1.822	0.177
HER-2	Positive	41	49	90	1.822	0.177
Ki-67	<42.50	36	28	64	3.049	0.081
Ki-67	≥ 42.50	19	29	48	3.049	0.081
Molecular classification	Luminal A	0	1	1		0.063^a
	Luminal B(HER-2⁻)	10	3	13
	Luminal B(HER-2⁺)	28	25	53
	HER-2⁺	13	24	37
	Triple negative	3	4	7
Therapy cycle	<7	28	18	46	4.321	0.038
Therapy cycle	≥ 7	27	39	66	4.321	0.038
CEA (ng/mL)	<2.93	42	35	77	3.682	0.055
CEA (ng/mL)	≥ 2.93	11	21	32	3.682	0.055
CA153 (U/mL)	<19.14	35	31	66	1.300	0.254
CA153 (U/mL)	≥ 19.14	18	35	53	1.300	0.254
Hb (g/L)	<135.50	30	35	65	0.541	0.462
Hb (g/L)	≥ 135.50	25	22	47	0.541	0.462
WBC (×10^9/L)	<6.13	13	23	36	4.475	0.034
WBC (×10^9/L)	≥ 6.13	43	34	77	4.475	0.034
PLT (×10^9/L)	<247.50	27	17	44	4.356	0.037
PLT (×10^9/L)	≥ 247.50	28	40	68	4.356	0.037
LYM (×10^9/L)	<1.64	35	13	48	0.352	<0.001
LYM (×10^9/L)	≥ 1.64	20	44	64	0.352	<0.001
NEU (×10^9/L)	<4.70	25	33	58	1.735	0.188
NEU (×10^9/L)	≥ 4.70	30	24	54	1.735	0.188
Monocyte (×10^9/L)	<0.44	38	47	85	2.733	0.098
Monocyte (×10^9/L)	≥ 0.44	17	10	27	2.733	0.098
ALB (g/L)	<52.15	5	2	7		0.434^a
ALB (g/L)	≥ 52.15	41	43	84		0.434^a
NLR	<2.02	6	28	34	19.334	<0.001
NLR	≥ 2.02	49	29	78	19.334	<0.001
PLR	<161.50	18	42	60	18.878	<0.001
PLR	≥ 161.50	37	15	52	18.878	<0.001
LMR	<6.39	45	29	74	11.954	0.001
LMR	≥ 6.39	10	28	38	11.954	0.001
SII	<598.50	13	32	45	12.304	<0.001
SII	≥ 598.50	42	25	67	12.304	<0.001

^a Fisher exact probability method. BC: Breast cancer; NAC: Neoadjuvant chemotherapy; pCR: Pathological complete response; IDC: Invasive ductal carcinoma; ER: Estrogen receptor; PR: Progesterone receptor; HER-2: Human epidermal growth factor receptor-2; CEA: Carcinoembryonic antigen; CA153: Carbohydrate antigen 153: WBC: White blood cell; Hb: Hemoglobin; PLT: Platelet; LYM: Lymphocyte; ALB: Albumin; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; SII: Systemic immune inflammation index.